Products
Platform
Research
Market
Learn
Compare HDFC Pharma And Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.08 | 1.88 |
NAV | ₹17.44 | ₹41.02 |
Fund Started | 14 Sep 2023 | 25 Jun 2018 |
Fund Size | ₹1909.30 Cr | ₹6161.81 Cr |
Exit Load | Exit load of 1%, if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.08
1.88
NAV
₹17.44
₹41.02
Fund Started
14 Sep 2023
25 Jun 2018
Fund Size
₹1909.30 Cr
₹6161.81 Cr
Exit Load
Exit load of 1%, if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 7.53% | 3.99% |
3 Year | - | 29.38% |
5 Year | - | 20.51% |
1 Year
7.53%
3.99%
3 Year
-
29.38%
5 Year
-
20.51%
Holding Analysis
Equity | 98.89% | 95.88% |
Cash | 1.11% | 4.12% |
Equity
98.89%
95.88%
Cash
1.11%
4.12%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.39% |
Divi's Laboratories Ltd. | 8.30% |
Glenmark Pharmaceuticals Ltd. | 6.78% |
Lupin Ltd. | 6.73% |
Cipla Ltd. | 6.56% |
Ipca Laboratories Ltd. | 4.62% |
Alkem Laboratories Ltd. | 3.94% |
Torrent Pharmaceuticals Ltd. | 3.74% |
Krishna Institute of Medical Sciences Ltd | 3.73% |
Laurus Labs Ltd. | 3.62% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.71% |
Dr. Reddy's Laboratories Ltd. | 9.47% |
Divi's Laboratories Ltd. | 9.23% |
Cipla Ltd. | 7.39% |
Aurobindo Pharma Ltd. | 6.53% |
Lupin Ltd. | 5.44% |
Alkem Laboratories Ltd. | 4.00% |
Mankind Pharma Ltd. | 3.50% |
Biocon Ltd. | 3.21% |
Gland Pharma Ltd. | 2.88% |
Fund Manager
Name | Dhruv Muchhal | Dharmesh Kakkad |
Start Date | 22 Jun 2023 | 05 Feb 2020 |
Name
Dhruv Muchhal
Dharmesh Kakkad
Start Date
22 Jun 2023
05 Feb 2020
About Fund
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 14 Sep 2023 | 25 Jun 2018 |
Description
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
14 Sep 2023
25 Jun 2018
